Stephen B. Hanauer

Dr. Stephen B. Hanauer

Gastroenterology
259 E Erie St Ste 1600, Lavin Family Pavilion, 
Chicago, IL 
Offers Telehealth
48 Years of Experience
259 E Erie St Ste 1600, Lavin Family Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Hanauer is a Gastroenterologist in Chicago, Illinois. Dr. Hanauer has been practicing medicine for over 48 years and is rated as an Experienced provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 247 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Illinois At Chicago College Of Medicine, 1977
Residency
University of Chicago
Specialties
Gastroenterology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Gastroenterology (Certified)
Fellowships
University of Chicago
Hospital Affiliations
Loyola University Medical Center
Northwestern Memorial Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

259 E Erie St Ste 1600, Lavin Family Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Hanauer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Colitis
Crohn's Disease

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

247 Total Publications

The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease.
The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease.
Journal: Expert review of gastroenterology & hepatology
Published: May 26, 2025
Similar Doctors
Darren M. Brenner
Distinguished in Opioid Induced Constipation
Dr. Darren M. Brenner
Gastroenterology
Distinguished in Opioid Induced Constipation
Dr. Darren M. Brenner
Gastroenterology
259 E Erie St Ste 1600, Lavin Family Pavilion, 
Chicago, IL 
 (0.1 miles away)
312-695-5620
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Darren Brenner is a Gastroenterologist in Chicago, Illinois. Dr. Brenner has been practicing medicine for over 23 years and is rated as an Elite provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome (IBS), Diarrhea, Gastrectomy, and Colonoscopy.

Advanced in Opioid Induced Constipation
Dr. Soojong Chae
Gastroenterology
Advanced in Opioid Induced Constipation
Dr. Soojong Chae
Gastroenterology

Endeavor Health Medical Group

2650 Ridge Ave, 
Evanston, IL 
 (12.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Soojong Chae is a Gastroenterologist in Evanston, Illinois. Dr. Chae is rated as an Advanced provider by MediFind in the treatment of Opioid Induced Constipation. Her top areas of expertise are Trichohepatoenteric Syndrome, Diarrhea, Chronic Idiopathic Constipation (CIC), Endoscopy, and Colonoscopy.

Rogelio Silva
Experienced in Opioid Induced Constipation
Dr. Rogelio Silva
Gastroenterology
Experienced in Opioid Induced Constipation
Dr. Rogelio Silva
Gastroenterology

Advocate Medical Group Gastroenterology

10500 S Cicero Ave, 
Oak Lawn, IL 
 (14.9 miles away)
708-424-1202
Languages Spoken:
English
See accepted insurances

Rogelio Silva is a Gastroenterologist in Oak Lawn, Illinois. Dr. Silva is rated as a Distinguished provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Angiodysplasia of the Colon, Gastrointestinal Bleeding, Chronic Erosive Gastritis, Gastrectomy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hanauer's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile